The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 04, 2020

Filed:

May. 03, 2018
Applicant:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Saar Gill, Philadelphia, PA (US);

Miriam Kim, Philadelphia, PA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 35/28 (2015.01); A61K 45/00 (2006.01); A61P 35/02 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 45/05 (2013.01); A61P 35/02 (2018.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01);
Abstract

The present invention relates to compositions and methods of generating modified hematopoietic stem or progenitor cells. One aspect of the invention includes a modified hematopoietic stem or progenitor cell comprising a nucleic acid capable of decreasing expression of an endogenous gene or a portion thereof, wherein the endogenous gene encodes a polypeptide comprising an antigen domain targeted by a chimeric antigen receptor (CAR). Another aspect of the invention includes a method for generating a modified hematopoietic stem or progenitor cell. Also included are methods and pharmaceutical compositions comprising the modified cell for adoptive therapy and treating a condition, such as an autoimmune disease or cancer. In certain embodiments, the invention includes a modified hematopoietic stem or progenitor cell comprising a nucleic acid capable of decreasing expression of CD33. In certain embodiments, the invention includes compositions and methods for treating cancer comprising administering CD33 CAR-T cells and modified hematopoietic stem or progenitor cells that are resistant to CD33-targeted therapy.


Find Patent Forward Citations

Loading…